Head-to-head evidence
Olodaterol vs Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Olodaterol
Marketed by Boehringer Ingelheim
NCT00467740 · Phase 2 · completed
The study randomized 296 participants to placebo or one of four olodaterol doses, but the registry does not clearly report whether treatment assignment was blinded. Its primary outcome was a lung-function surrogate rather than a hard clinical outcome, and results were mixed across doses: only olodaterol 20 micrograms significantly improved trough FEV1 versus placebo at 4 weeks.
Vilanterol
Marketed by GlaxoSmithKline
NCT01706198 · Phase 3 · completed
The study randomized 4,233 participants to FF/VI or active usual care, but neither participants nor investigators were blinded. Its primary patient-reported asthma-control endpoint was a surrogate/soft measure and was met in favor of FF/VI (71% vs 56%; p<0.001), supporting moderate rather than strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olodaterol's landscape · Vilanterol's landscape